Efgartigimod Alfa, a drug designed to ameliorate symptoms of Generalised Myasthenia Gravis (gMG), has been reimbursed since April 2023 in Japan. The drug is priced at JPY 421,455 for Vyvgart® for intravenous infusion 400 mg as of September 2023. Center for Outcomes Research and Economic Evaluation for Health (C2H) calculate the price using a model for the Efgartigimod Alfa Cost-effectiveness. They then add a 5% usefulness premium and a 10% market premium.
The cost-effectiveness evaluation of Efgartigimod alfa targets two populations: acetylcholine receptor antibody-positive and antibody-negative patients. The comparators were prednisolone ± immunosuppressive drug ± acetylcholinesterase inhibitor.
The manufacturer did not conduct a systematic review in the base case analysis but evaluated the additional benefits of Efgartigimod alfa for patients with gMG as a whole. The academic group decided to evaluate based on scope. They assessed additional benefits for each population using the ADAPT trial.
The manufacturer conducted a cost-utility analysis using a Markov model, which had states of Efgartigimod alfa or the comparator as first-line treatments, intravenous immunoglobulin or plasma exchange as second-line treatments, eculizumab as third-line treatment (only for population [a]), and the best supportive care.
The Expert Committee of Cost-Effectiveness Evaluation accepted the following:
🌍 Today is World Diabetes Day! Managing diabetes effectively is key to a healthier life! Discover strategies for preoperative risk assessment, obesity management, and safe fasting during Ramadan. Let’s prioritise our health together! 💪
#SyenzaNews #WorldDiabetesDay #DiabetesManagement #RamadanFasting #ObesityManagement
🌍 How can self-collection methods improve cervical cancer screening?
A recent article from the National Cancer Institute explores the groundbreaking FDA approval for HPV tests that allow patients to safely collect their own vaginal samples in a healthcare setting. This innovation promises to enhance access to screening for underserved populations and could transform the future of cervical cancer prevention. Jump into the details and learn how this initiative is poised to address health disparities in the U.S.
#SyenzaNews #oncology #HealthcareInnovation #HealthTech #innovation
🌍 How can we combat the rising threat of Antimicrobial Resistance (AMR) in Africa?
The new guidance from Africa CDC presents a comprehensive framework for strengthening AMR surveillance. By implementing a One Health approach and enhancing collaboration, we can address the challenges posed by AMR and significantly improve public health outcomes across the continent.
Jump into the details of this critical initiative and discover how we can work together to forge a sustainable path forward!
#SyenzaNews #GlobalHealth #HealthcareInnovation #DataScience #AMR #OneHealth
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
